Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study

Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm, prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Shigeki, Nakanishi, Naohiko, Yokota, Isao, Imai, Kojiro, Yamada, Ayumu, Kawasaki, Takanori, Kasahara, Takeru, Okada, Takashi, Sawada, Takahisa, Matoba, Satoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747974/
https://www.ncbi.nlm.nih.gov/pubmed/36513734
http://dx.doi.org/10.1038/s41598-022-26150-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747974/
https://www.ncbi.nlm.nih.gov/pubmed/36513734
http://dx.doi.org/10.1038/s41598-022-26150-w

Ejemplares similares